Annual EBITDA
-$36.62 M
-$17.92 M-95.87%
December 1, 2023
Summary
- As of March 1, 2025, SKYE annual EBITDA is -$36.62 million, with the most recent change of -$17.92 million (-95.87%) on December 1, 2023.
- During the last 3 years, SKYE annual EBITDA has fallen by -$30.77 million (-525.72%).
- SKYE annual EBITDA is now -1881.46% below its all-time high of $2.06 million, reached on December 1, 2019.
Performance
SKYE EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$3.54 M
+$3.88 M+52.29%
September 1, 2024
Summary
- As of March 1, 2025, SKYE quarterly EBITDA is -$3.54 million, with the most recent change of +$3.88 million (+52.29%) on September 1, 2024.
- Over the past year, SKYE quarterly EBITDA has increased by +$1.01 million (+22.22%).
- SKYE quarterly EBITDA is now -121.86% below its all-time high of $16.20 million, reached on June 1, 2019.
Performance
SKYE Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$19.48 M
+$21.08 M+51.97%
September 1, 2024
Summary
- As of March 1, 2025, SKYE TTM EBITDA is -$19.48 million, with the most recent change of +$21.08 million (+51.97%) on September 1, 2024.
- Over the past year, SKYE TTM EBITDA has increased by +$16.55 million (+45.93%).
- SKYE TTM EBITDA is now -233.99% below its all-time high of $14.54 million, reached on March 1, 2020.
Performance
SKYE TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
SKYE EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -95.9% | +22.2% | +45.9% |
| 3 y3 years | -525.7% | -22.6% | -74.4% |
| 5 y5 years | -91.7% | -22.6% | -74.4% |
SKYE EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -374.6% | at low | -54.8% | +85.6% | -152.5% | +54.1% |
| 5 y | 5-year | -1881.5% | at low | -168.8% | +85.6% | -234.0% | +54.1% |
| alltime | all time | -1881.5% | at low | -121.9% | +85.6% | -234.0% | +54.1% |
Skye Bioscience EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$3.54 M(-52.3%) | -$19.48 M(-52.0%) |
| Jun 2024 | - | -$7.42 M(+63.0%) | -$40.57 M(+12.6%) |
| Mar 2024 | - | -$4.55 M(+14.8%) | -$36.03 M(-1.5%) |
| Dec 2023 | -$36.62 M(+95.9%) | -$3.97 M(-83.9%) | -$36.60 M(-13.8%) |
| Sep 2023 | - | -$24.63 M(+752.8%) | -$42.44 M(+105.0%) |
| Jun 2023 | - | -$2.89 M(-43.6%) | -$20.70 M(-1.4%) |
| Mar 2023 | - | -$5.12 M(-47.8%) | -$20.99 M(+12.3%) |
| Dec 2022 | -$18.70 M(+142.3%) | -$9.81 M(+239.7%) | -$18.70 M(+67.3%) |
| Sep 2022 | - | -$2.89 M(-9.2%) | -$11.17 M(+12.8%) |
| Jun 2022 | - | -$3.18 M(+12.9%) | -$9.91 M(+15.8%) |
| Mar 2022 | - | -$2.82 M(+23.2%) | -$8.56 M(+10.9%) |
| Dec 2021 | -$7.72 M(+31.9%) | -$2.29 M(+41.0%) | -$7.72 M(+14.4%) |
| Sep 2021 | - | -$1.62 M(-11.4%) | -$6.75 M(+8.1%) |
| Jun 2021 | - | -$1.83 M(-7.3%) | -$6.24 M(+10.3%) |
| Mar 2021 | - | -$1.98 M(+50.1%) | -$5.65 M(-3.4%) |
| Dec 2020 | -$5.85 M(-384.7%) | -$1.32 M(+18.1%) | -$5.85 M(-1051.9%) |
| Sep 2020 | - | -$1.11 M(-10.7%) | $614.80 K(-121.2%) |
| Jun 2020 | - | -$1.25 M(-42.7%) | -$2.90 M(-120.0%) |
| Mar 2020 | - | -$2.18 M(-142.2%) | $14.54 M(+607.4%) |
| Dec 2019 | $2.06 M(-110.8%) | $5.15 M(-211.2%) | $2.06 M(-122.2%) |
| Sep 2019 | - | -$4.63 M(-128.6%) | -$9.26 M(+37.7%) |
| Jun 2019 | - | $16.20 M(-210.5%) | -$6.73 M(-73.7%) |
| Mar 2019 | - | -$14.66 M(+137.7%) | -$25.58 M(+34.0%) |
| Dec 2018 | -$19.10 M | -$6.17 M(+194.2%) | -$19.10 M(+40.9%) |
| Sep 2018 | - | -$2.10 M(-21.2%) | -$13.56 M(+13.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2018 | - | -$2.66 M(-67.5%) | -$11.94 M(+19.7%) |
| Mar 2018 | - | -$8.18 M(+1203.7%) | -$9.98 M(+223.6%) |
| Dec 2017 | -$3.08 M(-2.5%) | -$627.10 K(+31.1%) | -$3.08 M(+48.9%) |
| Sep 2017 | - | -$478.20 K(-31.6%) | -$2.07 M(-15.3%) |
| Jun 2017 | - | -$698.70 K(-45.4%) | -$2.45 M(-24.2%) |
| Mar 2017 | - | -$1.28 M(-432.1%) | -$3.22 M(+2.0%) |
| Dec 2016 | -$3.16 M(-26.6%) | $385.40 K(-145.2%) | -$3.16 M(-32.7%) |
| Sep 2016 | - | -$852.20 K(-42.3%) | -$4.70 M(-0.9%) |
| Jun 2016 | - | -$1.48 M(+21.5%) | -$4.74 M(+2.7%) |
| Mar 2016 | - | -$1.22 M(+5.6%) | -$4.62 M(+7.2%) |
| Dec 2015 | -$4.31 M(+57.8%) | -$1.15 M(+28.9%) | -$4.31 M(-11.3%) |
| Sep 2015 | - | -$893.60 K(-34.0%) | -$4.85 M(+0.7%) |
| Jun 2015 | - | -$1.35 M(+49.2%) | -$4.82 M(+39.6%) |
| Mar 2015 | - | -$907.50 K(-46.6%) | -$3.45 M(+35.1%) |
| Dec 2014 | -$2.73 M(<-9900.0%) | -$1.70 M(+98.2%) | -$2.56 M(+200.6%) |
| Sep 2014 | - | -$857.60 K(-7493.1%) | -$850.40 K(<-9900.0%) |
| Jul 2014 | - | $11.60 K(-207.4%) | $4700.00(-220.5%) |
| Apr 2014 | - | -$10.80 K(-268.8%) | -$3900.00(-126.9%) |
| Jan 2014 | - | $6400.00(-356.0%) | $14.50 K(+55.9%) |
| Oct 2013 | $9200.00(+91.7%) | -$2500.00(-183.3%) | $9300.00(-44.3%) |
| Jul 2013 | - | $3000.00(-60.5%) | $16.70 K(+21.0%) |
| Apr 2013 | - | $7600.00(+533.3%) | $13.80 K(+137.9%) |
| Jan 2013 | - | $1200.00(-75.5%) | $5800.00(+26.1%) |
| Oct 2012 | $4800.00 | $4900.00(+4800.0%) | $4600.00(-1633.3%) |
| Jul 2012 | - | $100.00(-125.0%) | -$300.00(-25.0%) |
| Apr 2012 | - | -$400.00 | -$400.00 |
FAQ
- What is Skye Bioscience annual EBITDA?
- What is the all time high annual EBITDA for Skye Bioscience?
- What is Skye Bioscience annual EBITDA year-on-year change?
- What is Skye Bioscience quarterly EBITDA?
- What is the all time high quarterly EBITDA for Skye Bioscience?
- What is Skye Bioscience quarterly EBITDA year-on-year change?
- What is Skye Bioscience TTM EBITDA?
- What is the all time high TTM EBITDA for Skye Bioscience?
- What is Skye Bioscience TTM EBITDA year-on-year change?
What is Skye Bioscience annual EBITDA?
The current annual EBITDA of SKYE is -$36.62 M
What is the all time high annual EBITDA for Skye Bioscience?
Skye Bioscience all-time high annual EBITDA is $2.06 M
What is Skye Bioscience annual EBITDA year-on-year change?
Over the past year, SKYE annual EBITDA has changed by -$17.92 M (-95.87%)
What is Skye Bioscience quarterly EBITDA?
The current quarterly EBITDA of SKYE is -$3.54 M
What is the all time high quarterly EBITDA for Skye Bioscience?
Skye Bioscience all-time high quarterly EBITDA is $16.20 M
What is Skye Bioscience quarterly EBITDA year-on-year change?
Over the past year, SKYE quarterly EBITDA has changed by +$1.01 M (+22.22%)
What is Skye Bioscience TTM EBITDA?
The current TTM EBITDA of SKYE is -$19.48 M
What is the all time high TTM EBITDA for Skye Bioscience?
Skye Bioscience all-time high TTM EBITDA is $14.54 M
What is Skye Bioscience TTM EBITDA year-on-year change?
Over the past year, SKYE TTM EBITDA has changed by +$16.55 M (+45.93%)